PHARMACEUTICAL BASICS' TIMOLOL MALEATE IS FIRST ANDA APPROVAL
PHARMACEUTICAL BASICS' TIMOLOL MALEATE IS FIRST ANDA APPROVAL for a generic version of Merck's beta blocker Blocadren. The Pharmaceutical Basics Inc. (PBI) timolol ANDA was approved in 5 mg, 10 mg and 20 mg strengths on Jan. 10. The approval is effectively delayed until April 11, when Merck's patent for timolol expires. The timolol patent is also the effective patent for Merck's ophthalmic product Timoptic, which controls a much larger market than the heart drug Blocadren. Analyst estimates for Timoptic sales in the U.S. are in the $100-110 mil. range, while Blocadren sales are estimated in the $15-20 mil. range. On Jan. 11, FDA approved Danbury's ANDA for prazosin - the second generic version of Pfizer's Minipress (prazosin). Zenith received an ANDA approval for prazosin in September. Marketing of prazosin is delayed until May 16, 1989, according to FDA's "Orange Book."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth